Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03143322
Other study ID # UC-0107/1603
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 24, 2018
Est. completion date July 24, 2027

Study information

Verified date December 2023
Source UNICANCER
Contact Saliha GHANEM, PhD
Phone +33(0)1 80 50 12 98
Email s-ghanem@unicancer.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Bone metastases occur frequently during the evolution of solid tumors, either isolated or associated with visceral metastases. The incidence varies between 20 and 85% depending on the primary cancer. Breast, prostate, and lung cancers are responsible for 70% of bone metastases. Cancer with bone metastases compared to other metastatic sites is considered as associated with a better prognosis, particularly for breast and prostate cancer. Bone metastases may be present at diagnosis (synchronous metastasis) or appear at a later time (metachronous metastasis). The concept of "oligometastases" was proposed in patients with about 3 up to 5 metastases (without restriction on the primary site) and associated with an intermediate prognosis. It was hypothesized that local treatment with curative intent, aiming at the few metastatic sites, would yield long-term survival probabilities, along with systemic therapies. Long-term survivors have been reported after curative-intent treatment of metastasis in sarcoma and colorectal cancers with liver or lung metastasis. We chose to focus on bone metastasis because of their high incidence, their impact on the patient's quality of life and autonomy, and their accessibility to potentially curative radiotherapy. The systemic treatment of metastatic cancer includes hormonal therapy (breast and prostate cancer), biologically-targeted drugs and chemotherapy (all cancers). Stereotactic radiotherapy is a highly accurate technique was initially developed for performing the radiosurgery of brain tumors in patients for whom it was deemed be too difficult to proceed to classical excision surgery. In this process, a high total dose of radiation is delivered in a single fraction to a well-defined intra-cranial target. The concept of radiotherapy in stereotactic conditions was extended to one or several fractions delivered to small volumes primary tumors/ metastases in extra-cranial sites (Stereotactic Body RadioTherapy [SBRT]). At present, high control rates have been achieved for lung metastases. Similarly, very high local control rates have been reported in bone metastases after stereotactic radiotherapy. In this protocol, our purpose is to demonstrate, via a randomized phase III trial, that high doses of radiotherapy, delivered in stereotactic conditions to the bone metastases (between 1 and 5 metastases) in solid tumor patients is able to improve the survival without progression.


Recruitment information / eligibility

Status Recruiting
Enrollment 196
Est. completion date July 24, 2027
Est. primary completion date January 24, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Patients older than 18 years and younger than 75 years 2. Good general condition: WHO performance status = 2 3. Patients with histological proof of breast, non-small cell lung, or prostate cancer Note: Histological proof can be done on the primitive tumour and/or adenopathy and/or metastatic site. 4. Absence of co-morbidity contra-indicating radio-chemotherapy or surgery 5. Primary tumor accessible to curative-intent treatment (surgery, chemoradiation…) for patients with synchronous metastases 6. Patients with between 1 and 5 synchronous or metachronous bone metastases as defined by NaF-PET or conventional SPECT-CT scan and spinal MRI (if necessary) within 6 weeks before randomization) 7. Bones metastases treatable by SBRT 8. Primary cancer considered to be controlled or accessible to curative-intent treatment (surgery, chemoradiation…) in case of locoregional recurrence for metachronous bone oligo-metastatic disease 9. Women of childbearing potential and male patients must agree to use adequate contraception for the duration of study participation and up to 3 months following completion of therapy 10. Patients who have received the information sheet, dated and signed the informed consent form 11. Affiliated to the social security system Exclusion Criteria: 1. Visceral metastases as defined by FDG-PET (F-Choline-PET or PSMA PET-CT for prostate cancer) and cerebral CT or MRI performed. 2. Previous systemic therapy for metastasis for patients with metachronous metastasis. Prostate and breast cancer patients remain eligible if hormonal treatment was initiated 6 months before enrollment 3. All bone metastasis requiring surgical treatment (spinal cord compression, fracture…) 4. More than 5 bone metastases as defined by NaF-PET or conventional SPECT-CT scan and spinal MRI (if spinal bone metastases on NaF-PET) 5. Previous cancer within the 5 years before inclusion (except basal cell carcinoma of the skin, in situ carcinoma of the uterine cervix) 6. Previous radiotherapy on bone metastasis (e.g: antalgic radiotherapy) 7. Patient enrolled in another therapeutic trial 8. Pregnant women or breast feeding mothers, 9. Hypersensitivity to the active substance (FDG and NaF or F-Choline or PSMA for prostate cancer) or to any of the excipients 10. Contraindication to MRI (in case of spinal metastases) 11. Patients deprived of liberty or placed under the authority of a tutor. Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial. Patients unable to understand the purpose of the study (language, etc.).

Study Design


Intervention

Radiation:
SBRT
SBRT will be added to systemic (standard) treatment of bone metastases.

Locations

Country Name City State
France ICO - Site Paul Papin Angers
France Centre Marie Curie Arras
France Hôpital Privé Les Bonnettes Arras
France Institut Sainte Catherine Avignon
France Centre Pierre Curie Beuvry
France Clinique Ambroise Pare Beuvry
France Clinique Tivoli Ducos Bordeaux
France Institut Bergonié Bordeaux
France Hôpital Métropole Savoie Chambéry
France Pôle Leonard de Vinci Chambray-lès-Tours
France Centre Amethyst CROM Creil
France Hôpital Henri Mondor Créteil
France Centre Léonard de Vinci Dechy
France Centre Georges Francois Leclerc Dijon
France Institut de Cancérologie de Bourgogne Dijon
France Chu Grenoble Grenoble
France Centre de Radiothérapie Hartmann Levallois Perret
France Centre Oscar Lambret Lille
France Hôpital Privé Le Bois Lille
France Centre Léon Bérard Lyon
France Institut Paoli Calmettes Marseille
France Centre de Cancérologie du Grand Montpellier Montpellier
France Institut de Cancérologie de Lorraine Nancy
France Institut de Cancérologie de l'Ouest Nantes
France Centre Catalan D'Oncologie Perpignan
France Institut Jean Godinot Reims
France Centre Eugène Marquis Rennes
France Centre Henri Becquerel Rouen
France Centre d'oncologie et radiothérapie Saint-Jean Saint-doulchard
France CHU Saint-Etienne Saint-Étienne
France GCS RISSA - Institut de cancérologie Paris Nord Sarcelles
France Centre Marie Curie Valence
France Clinique des dentellières Valenciennes
France Centre d'Oncologie Saint Yves Vannes

Sponsors (2)

Lead Sponsor Collaborator
UNICANCER National Cancer Institute, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression Free Survival To evaluate the impact of SBRT on Progression-Free Survival (PFS) at 1 year according to RECIST 1.1 and PERCIST 1.0 Criteria 1 year
Secondary PFS at 2 and 3 years Progression-Free Survival (PFS) at 2 and 3 years will be evaluated according to RECIST 1.1 and PERCIST 2 years and 3 years after treatment
Secondary Bone progression free survival at 1, 2 and 3 years Distant bone progression at 2 and 3 years will be evaluated according to RECIST Criteria 1.1 and at 1 year according to RECIST Criteria 1.1 and PERCIST 1, 2 and 3 years after treatment
Secondary Local control at 1, 2 and 3 years Local control will be evaluated at 1, 2 and 3 years according to RECIST Criteria 1.1 and PERCIST 1, 2 and 3 years after treatment
Secondary Cancer-specific survival The length of time from the start of treatment for the disease until the death identified as being due to the specified cancer. 1, 2 and 3 years after treatment
Secondary Overall survival The length of time from the start of treatment for the disease until patients are still alive. 1, 2 and 3 years after treatment
Secondary SBRT toxicities according CTCAE 4.0 scale 1, 2 and 3 years after treatment
Secondary Patient's Quality of life self-administered questionnaire at baseline, 6 weeks after randomization, and 3 months, 6 months and 1, 2 and 3 years after treatment
Secondary Pain score according to Numeric Scale related to pain medication at baseline, once a week during 2 weeks and 6 weeks after randomization, and at 3 months, 6 months and 1, 2 and 3 years after treatment
Secondary Cost utility QALYs (Quality-Adjusted Life Years) and ICERs (Incremental Cost-Effectiveness Ratios) calculation based on EQ-5D-3L questionnaire. 6 weeks after randomization
See also
  Status Clinical Trial Phase
Withdrawn NCT04872608 - A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer Phase 1
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Completed NCT02506556 - Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer Phase 2
Recruiting NCT05534438 - A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer Phase 2
Recruiting NCT03368729 - Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer Phase 1/Phase 2
Completed NCT04103853 - Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer Phase 1
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Active, not recruiting NCT03147287 - Palbociclib After CDK and Endocrine Therapy (PACE) Phase 2
Not yet recruiting NCT06062498 - Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer Phase 2
Recruiting NCT05383196 - Onvansertib + Paclitaxel In TNBC Phase 1/Phase 2
Recruiting NCT04095390 - A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer Phase 2
Active, not recruiting NCT04432454 - Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Phase 2
Recruiting NCT03323346 - Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer Phase 2
Recruiting NCT05744375 - Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab Phase 2
Completed NCT02924883 - A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy Phase 2
Completed NCT01881230 - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Phase 2/Phase 3
Completed NCT01942135 - Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) Phase 3
Active, not recruiting NCT04448886 - Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Phase 2
Completed NCT01401959 - Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy Phase 2
Terminated NCT04720664 - Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer Phase 2